Wenlin Zeng, Ph.D., is the VP of Early Stage CMC. Dr. Zeng has over 20 years of experience in drug discovery and drug development in the biopharmaceutical industry.
Prior to joining Adagene, Dr. Zeng was the Senior Director of Upstream Process Development responsible for both early and late stage programs at Gilead Sciences, Inc. Prior to that, she was the Senior Director of Cell Line and Upstream Process Development at Forty-Seven Inc., where she was responsible for cell line, upstream process development and manufacturing for a number of programs, including magrolimab. Prior to Forty-Seven, Dr. Zeng held leadership positions at multiple biopharmaceutical companies, including NGM Bio, GSK, MedImmune, and Abgenix.
Dr. Zeng began her career in biopharmaceutical industry after completing her post-doctoral training at Stanford University. She earned her Ph.D. in Biochemistry from The University of Iowa and B.S. in Cell Biology from Wuhan University in China.